Please ensure Javascript is enabled for purposes of website accessibility

Why Cardiff Oncology Stock Is Crashing Today

By Keith Speights - Jan 15, 2021 at 12:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech presented data from an early-stage study of its experimental colorectal cancer drug.

What happened

Shares of Cardiff Oncology (CRDF -2.34%) were trading 19.8% lower as of 11:44 a.m. EST on Friday. The big drop came after the company presented data from a phase 1b/2 study of onvansertib in treating KRAS-mutated metastatic colorectal cancer (mCRC) at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.

So what

Biotech stocks don't plunge when investors are happy with clinical trial updates. It's obvious that at least some investors were disappointed by Cardiff's latest news.

Man wearing coat and tie holding a red line with an arrow pointing downward

Image source: Getty Images.

Only 12 patients in the phase 1b/2 study were evaluable in time to be included in the ASCO presentation. Five of them achieved a partial response (some tumor shrinkage) with four patients having confirmed partial responses. Eight demonstrated what Cardiff described as "durable responses" of at least six months.

In addition, the company stated that onvansertib in combination with chemotherapy was found to be safe and well-tolerated. Cardiff said that 9% of adverse events reported in the study were grade 3 (severe) or grade 4 (life-threatening).

While some investors seem to have been hoping for better results, Cardiff and the team involved with the study were upbeat. Lead investigator Daniel Ahn of the Mayo Clinic Cancer Center in Arizona said that the data "highlights the promise of onvansertib plus standard-of-care as an effective second-line treatment for patients with KRAS-mutated mCRC." Cardiff Oncology CEO Mark Erlander stated that the company is "pleased with the continued advancement of our KRAS-mutated mCRC clinical study."

Now what

Cardiff is now moving forward with the phase 2 part of its study of onvansertib, which is expected to enroll 26 patients across six trial sites.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cardiff Oncology, Inc. Stock Quote
Cardiff Oncology, Inc.
$1.25 (-2.34%) $0.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.